About Bendamustine Hydrochloride API
Therapeutic Category Oncology
CAS Number
3543-75-7
API Technology
Synthetic
Dose Form
Injectable
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, EUDMF, Korea DMF
Mechanism of Action
Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.
Indication
TREANDA for Injection is an alkylating drug indicated for treatment of patients with:
- Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximabcontaining regimen.
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Bortezomib
Oncology
Cabazitaxel
Oncology
Cabozantinib S-Malate
Oncology
Capecitabine
Oncology
Carfilzomib
Oncology
Decitabine
Oncology
Deucravacitinib
Oncology
Eribulin Mesylate
Oncology
Capivasertib
Oncology
Abiraterone Acetate
Oncology
Apalutamide (Amorphous & Form B)
Oncology
Azacitidine
Oncology
Cabozantinib Hydrochloride
Oncology
Bendamustine Hydrochloride
Oncology
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.